AbbVie Says Canada's Drug Agency Has Issued Its First-Ever Time-limited Reimbursement Recommendation For EPKINLY (Epcoritamab)

This recommendation recognizes the unmet need of adult patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy.

EPKINLY has also received a positive recommendation for the same indication from INESSS to list it in Quebec contingent on submission and reassessment of phase III clinical data once available.

EPKINLY is being co-developed by AbbVie and Genmab as part of their oncology collaboration.